ProCE Banner Activity

An Expert’s Guide to ASH 2020: A Preview of the Top Abstracts

Conference Coverage
Clinical Thought
Review experts perspectives on the most clinically relevant data on malignant and nonmalignant hematology results to be presented at the ASH 2020 annual meeting, including key insights and the latest data you need to understand and integrate into your practice.

Released: December 02, 2020

Expiration: December 01, 2021

Share

Faculty

Hanny Al-Samkari

Hanny Al-Samkari, MD

Assistant Professor
Harvard Medical School
Attending Hematologist and Clinical Investigator
Division of Hematology Oncology
Massachusetts General Hospital
Boston, Massachusetts

Jorge Cortes

Jorge Cortes, MD

Professor of Medicine
Deputy Chair, Department of Leukemia
M.D. Anderson Cancer Center
Houston, Texas

Jeffrey P. DONOTUSESharman

Jeffrey P. DONOTUSESharman, MD

Medical Oncologist
Willamette Valley Cancer Institute and Research Center
Springfield, Oregon

Amy Esposito

Amy Esposito, FNP-C

Nurse Practitioner
Rocky Mountain Cancer Center
Aurora, Colorado

Shaji K. Kumar

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Consultant, Division of Hematology
Professor of Medicine
Chair, Myeloma, Amyloidosis and Dysproteinemia Group
Research Chair, Division of Hematology
Mayo Clinic
Rochester, Minnesota

Sagar Lonial

Sagar Lonial, MD, FACP

Chair and Professor 
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

John L. Marshall

John L. Marshall, MD

Associate Professor, Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Washington, DC

Mark A. Schroeder

Mark A. Schroeder, MD

Associate Professor of Medicine
Division of Oncology
Department of Medicine
Washington University School of Medicine in St Louis
St Louis, Missouri

Sujit Sheth

Sujit Sheth, MD

Professor
Department of Pediatrics
Weill Cornell Medicine
New York, New York

Srdan Verstovsek

Srdan Verstovsek, MD, PhD

Professor
Division of Cancer Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Eunice S. Wang

Eunice S. Wang, MD

Chief, Leukemia and Benign Hematology Service
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Provided by

ProCE Banner

Supporters

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Epizyme, Inc.

GlaxoSmithKline

Incyte Corporation

Janssen Biotech

Karyopharm Therapeutics Inc.

Novartis

PharmaEssentia Corp

Seagen

Takeda Oncology

Faculty Disclosure

Primary Author

Hanny Al-Samkari, MD

Assistant Professor
Harvard Medical School
Attending Hematologist and Clinical Investigator
Division of Hematology Oncology
Massachusetts General Hospital
Boston, Massachusetts

Hanny Al-Samkari, MD, has disclosed that he has received consulting fees from Agios, Argenx, Dova, and Rigel and funds for research support from Agios, Amgen, and Dova.

Jorge Cortes, MD

Professor of Medicine
Deputy Chair, Department of Leukemia
M.D. Anderson Cancer Center
Houston, Texas

Jorge Cortes, MD, has disclosed that he has received consulting fees from Novartis, Pfizer, and Takeda and funds for research support from Novartis, Pfizer, Sun Pharma, and Takeda.

Jeffrey P. DONOTUSESharman, MD

Medical Oncologist
Willamette Valley Cancer Institute and Research Center
Springfield, Oregon

Jeff P. Sharman, MD, has disclosed that he has received consulting fees from AbbVie, AstraZeneca, Genentech, Pharmacyclics, and TG Therapeutic and funds for research support from AbbVie, AstraZeneca, Genentech, Gilead Sciences, Pharmacyclics, and TG therapeutics.

Amy Esposito, FNP-C

Nurse Practitioner
Rocky Mountain Cancer Center
Aurora, Colorado

Amy E. DeZern, MD, MHS, has disclosed that she has received consulting fees from Astex and Celgene.

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Consultant, Division of Hematology
Professor of Medicine
Chair, Myeloma, Amyloidosis and Dysproteinemia Group
Research Chair, Division of Hematology
Mayo Clinic
Rochester, Minnesota

Shaji Kumar, MD, has disclosed that he has received consulting fees from AbbVie, Bristol-Myers Squibb/Celgene, Genentech, Janssen, Oncopeptides, and Takeda and funds for research support from AbbVie, Bristol-Myers Squibb/Celgene, Genentech, Janssen, MedImmune, Takeda, and TeneoBio.

Sagar Lonial, MD, FACP

Chair and Professor 
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Sagar Lonial, MD, has disclosed that he has received consulting fees from Amgen, Bristol-Myers Squibb/Celgene, GlaxoSmithKline, Janssen, Karyopharm, Merck, and Novartis.

John L. Marshall, MD

Associate Professor, Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Washington, DC

John M. Burke, MD, has disclosed that he has received consulting fees from AbbVie, Adaptive Biotechnologies, AstraZeneca, BeiGene, Epizyme, Kura, MorphoSys, Roche/Genentech, and Verastem and fees for non-CME/CE services from BeiGene and Seattle Genetics.

Mark A. Schroeder, MD

Associate Professor of Medicine
Division of Oncology
Department of Medicine
Washington University School of Medicine in St Louis
St Louis, Missouri

Mark A. Schroeder, MD, has disclosed that he has received consulting fees from AbbVie, Amgen, Incyte, Merck, Sanofi Genzyme, and Takeda; funds for research support from Amgen, Celgene, Cellect, Fortis, Genentech, Incyte, Janssen, PBD, Sanofi Genzyme, and Seattle Genetics; and fees for non-CME/CE services from Astellas, Dova, FlatIron, Gilead, GlaxoSmithKline, Incyte, Novo Nordisk, Partners Therapeutics, Pfizer, and Sanofi Genzyme.

Sujit Sheth, MD

Professor
Department of Pediatrics
Weill Cornell Medicine
New York, New York

Sujit Sheth, MD, has disclosed that he has received consulting fees from Agios, Bristol-Myers Squibb/Celgene, and CRISPR/Vertex and funds for research support from Bristol-Myers Squibb/Celgene, DisperSol, and La Jolla.

Srdan Verstovsek, MD, PhD

Professor
Division of Cancer Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Srdan Verstovsek, MD, PhD, has disclosed that he has received consulting fees from Bristol-Myers Squibb/Celgene, Constellation, Disc Medicine, Incyte, Novartis, Pharma Essentia, Protagonist, and Sierra and funds for research support from AbbVie, AstraZeneca, Blueprint, Celgene, CTI BioPharma, Galecto, Incyte, Ital Pharma, Kartos, Novartis, Promedior, Protagonist, Sierra Oncology, and Telios.

Eunice S. Wang, MD

Chief, Leukemia and Benign Hematology Service
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York

Eunice S. Wang, MD, has disclosed that she has received consulting fees from AbbVie, Agios, Amgen, Astellas, Celyad, Daiichi Sankyo, Jazz, Kite, and Pfizer and fees for non-CME/CE services from Pfizer and Stemline.